Urinary iron excretion in young thalassemic patients receiving combined chelation treatment with deferoxamine and deferiprone

Journal of Pediatric Hematology/Oncology

Volumn 29, Issue 9, 2007, Pages 598-601

  Christoforidis, Athanasios ^a   Zevgaridou, Eleni ^a   Tsatra, Ioanna ^a   Perifanis, Vassilios ^a   Vlachaki, Efthimia ^a   Papassotiriou, Ioannis ^b   Apostolakou, Filia ^b   Athanassiou Metaxa, Miranda ^a  

^a Aristotle University Medical School   (Greece)

^b AGHIA SOPHIA CHILDREN S HOSPITAL   (Greece)

Author keywords

thalassemia major; Combined therapy; Deferiprone; Deferoxamine; Urinary iron excretion

Indexed keywords

DEFERIPRONE; DEFEROXAMINE;

ADULT; ARTICLE; BETA THALASSEMIA; CHELATION THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; FEMALE; FERRITIN BLOOD LEVEL; HUMAN; MALE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; URINALYSIS; URINARY EXCRETION;

ADOLESCENT; ADULT; BETA-THALASSEMIA; DEFEROXAMINE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IRON; IRON CHELATING AGENTS; MALE; PYRIDONES; TREATMENT OUTCOME;

EID: 34548384760     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e318142b51e     Document Type: Article

References (18)

1. Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Survival and complications in thalassemia. Ann N Y Acad Sci. 2005;1054:40-47.
2. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood. 1997;89:739-761.
3. Victor Hoffbrand A. Deferiprone therapy for transfusional iron overload. Best Pract Res Clin Haematol. 2005;18:299-317.
4. Went A, Roggero S, Vinciguerra T, et al. Deferiprone: new insight. Ann N Y Acad Sci. 2005;1054:169-174.
5. Kattamis A. Combined therapy with deferoxamine and deferiprone. Ann N Y Acad Sci. 2005;1054:175-182.
6. Giardina PJ, Grady RW. Chelation therapy in beta-thalassemia: an optimistic update. Semin Hematol. 2001;38:360-366.
7. Origa R, Bina P, Agus A, et al. Combined therapy with deferiprone and desferrioxamine in thalassemia major. Haematologica. 2005;90:1309-1314.
8. Link G, Konijn AM, Breuer W, et al. Exploring the "iron shuttle" hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture. J Lab Clin Med. 2001;138:130-138.
9. Kattamis A, Kassou C, Berdousi H, et al. Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion. Haematologica. 2003;88:1423-1425.
10. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307-310.
11. Wonke B, Wright C, Hoffbrand AV. Combined therapy with deferiprone and desferrioxamine. Br J Haematol. 1998;103:361-364.
12. Mourad FH, Hoffbrand AV, Sheikh-Taha M, et al. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients. Br J Haematol. 2003;121:187-189.
13. Daar S, Pathare AV. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload. Ann Hematol. 2006;85:315-319.
14. Kolnagou A, Kontoghiorghes GJ. Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators. Hemoglobin. 2006;30:239-249.
15. Christoforidis A, Perifanis V, Athanassiou-Metaxa M. Combined chelation therapy improves glucose metabolism in patients with beta-thalassaemia major. Br J Haematol. 2006;135:271-272.
16. Porter JB, Davis BA. Monitoring chelation therapy to achieve optimal outcome in the treatment of thalassaemia. Best Pract Res Clin Haematol. 2002;15:329-368.
17. Hussain MA, Green N, Flynn DM, et al. Effect of dose, time, and ascorbate on iron excretion after subcutaneous desferrioxamine. Lancet. 1977;1:977-979.
18. Pippard MJ. Desferrioxamine-induced iron excretion in humans. Baillieres Clin Haematol. 1989;2:323-343.